Zacks Research Issues Positive Outlook for BHC Earnings

Bausch Health Cos Inc. (NYSE:BHC) – Zacks Research increased their Q1 2027 earnings per share estimates for Bausch Health Cos in a research note issued on Wednesday, August 19th. Zacks Research analyst Team now expects that the company will post earnings of $0.84 per share for the quarter, up from their prior estimate of $0.80. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q2 2027 earnings at $0.91 EPS, Q3 2027 earnings at $1.07 EPS, Q4 2027 earnings at $1.02 EPS, FY2027 earnings at $3.84 EPS, Q1 2028 earnings at $0.65 EPS, Q2 2028 earnings at $0.86 EPS and FY2028 earnings at $3.04 EPS.

A number of other equities research analysts have also issued reports on the stock. Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Royal Bank Of Canada cut their price target on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research note on Monday, April 27th. Finally, Weiss Ratings upgraded Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos Price Performance

Shares of BHC opened at $6.84 on Friday. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -2.31 and a beta of 0.38. Bausch Health Cos has a fifty-two week low of $4.33 and a fifty-two week high of $8.00. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.44 and a quick ratio of 1.08. The business’s 50-day moving average is $5.33 and its 200-day moving average is $5.46.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%.The firm had revenue of $2.83 billion during the quarter, compared to the consensus estimate of $2.59 billion.

Insider Activity

In related news, insider Aimee J. Lenar sold 36,827 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total value of $258,893.81. Following the sale, the insider owned 334,853 shares of the company’s stock, valued at $2,354,016.59. The trade was a 9.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Hedge Funds Weigh In On Bausch Health Cos

Several institutional investors have recently added to or reduced their stakes in BHC. Public Employees Retirement System of Ohio bought a new stake in Bausch Health Cos during the second quarter worth about $2,565,000. Bank of America Corp DE acquired a new position in shares of Bausch Health Cos in the 2nd quarter worth approximately $2,816,000. Paulson & CO. Inc. bought a new stake in Bausch Health Cos during the 2nd quarter worth approximately $361,151,000. Man Group plc acquired a new stake in Bausch Health Cos during the 2nd quarter valued at $7,157,000. Finally, Biglari Capital CORP. acquired a new stake in Bausch Health Cos during the 2nd quarter valued at $202,475,000. 78.65% of the stock is owned by institutional investors.

Key Bausch Health Cos News

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Improving Bausch + Lomb outlook: A recent analysis highlighted Bausch + Lomb’s 9% year-over-year revenue growth in the second quarter, margin expansion and strong operating cash flow. Growth in premium intraocular lenses and branded pharmaceuticals could support a better product mix, higher EBITDA and debt reduction. Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine
• Neutral Sentiment: Zacks raised multiple earnings forecasts: Zacks Research increased its estimates for 2026 and 2027, including FY2026 EPS from $3.93 to $4.24 and FY2027 EPS from $3.59 to $3.84. Estimates for several quarterly periods through 2028 were also raised modestly. However, Zacks retained a Strong Sell rating, limiting the positive impact of the revisions. Bausch Health Cos analyst coverage
• Negative Sentiment: Insider selling adds pressure: Aimee Lenar sold 36,827 BHC shares for approximately $258,894, reducing her position by 9.91%. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which makes it a less concerning signal than discretionary selling, but it may still weigh modestly on sentiment. Aimee Lenar Sells 36,827 Shares of Bausch Health Cos

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.